Hematopatholgy Service, Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Hematopatholgy Service, Department of Pathology and Hematology Research Center, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Ann Hematol. 2019 Jan;98(1):169-173. doi: 10.1007/s00277-018-3498-z. Epub 2018 Oct 11.
Primary central nervous system lymphoma (PCNSL) is a rare specific subtype of non-Hodgkin lymphoma limited to the brain, leptomeninges, spinal cord, or eyes without any systemic presentation and relapse which mostly takes place in CNS. In more than 95% of patients, it is of diffuse large B cell lymphoma (DLBCL) type. Categorizing PCNSL to germinal center cell like or activated B cell like, as we usually do for DLBCL NOS, may not be applicable for predicting outcome. Possible prognostic significance of MYC, BCL2, and/or BCL6 rearrangements may be important given what we know about their impact in systemic DLBCL, but we have limited knowledge about the status of double or triple hit molecular changes in PCNSL. Here, we have investigated prevalence of these molecular alterations in PCNSL. Two independent tissue microarrays constructed from 78 formalin-fixed paraffin-embedded blocks of confirmed PCNSL were tested for rearrangement of MYC, BCL2, and BCL6 by interphase fluorescent in situ hybridization (FISH) using break apart dual color probes. BCL6 translocation was detected in 15 (12%) cases. Translocation involving MYC and BCL2 was identified in 3 cases (3.8%) and 1 case (1.3%) respectively. One double hit lymphoma was discovered with both MYC/BCL2 translocation (1.3%). To the best of our knowledge, few organized studies have been conducted for MYC, BCL2, and/or BCL6 rearrangement in PCNSL. This study is evaluating large number of PCNSL. Double or triple hit events which are rarely seen in PCNSL.
原发性中枢神经系统淋巴瘤(PCNSL)是一种罕见的非霍奇金淋巴瘤特殊亚型,局限于脑、软脑膜、脊髓或眼,无任何全身表现和复发,主要发生在中枢神经系统。在超过 95%的患者中,它是弥漫性大 B 细胞淋巴瘤(DLBCL)类型。将 PCNSL 分类为生发中心细胞样或激活 B 细胞样,就像我们通常对 DLBCLNOS 所做的那样,可能不适用于预测预后。MYC、BCL2 和/或 BCL6 重排的可能预后意义可能很重要,因为我们知道它们对系统性 DLBCL 的影响,但我们对 PCNSL 中双或三打击分子变化的状态知之甚少。在这里,我们研究了这些分子改变在 PCNSL 中的流行情况。使用分离双颜色探针通过间期荧光原位杂交(FISH),对 78 个福尔马林固定石蜡包埋的确诊 PCNSL 组织微阵列进行了 MYC、BCL2 和 BCL6 重排的检测。在 15 例(12%)病例中检测到 BCL6 易位。在 3 例(3.8%)和 1 例(1.3%)病例中分别鉴定出涉及 MYC 和 BCL2 的易位。发现了 1 例具有 MYC/BCL2 易位的双打击淋巴瘤(1.3%)。据我们所知,针对 PCNSL 中的 MYC、BCL2 和/或 BCL6 重排进行的有组织研究很少。本研究评估了大量的 PCNSL。在 PCNSL 中很少见的双打击或三打击事件。